Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of \[14C\] Prucalopride Succinate in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly Prucalopride Succinate or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.

Key facts

Study ID

NCT01807000

Run by

Shire

People needed

6

Starts

2013-03-18

Expected to finish

2013-04-28

Last updated by the study team

2021-06-10

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Males aged between 18 and 50 years, inclusive
• Body mass index (BMI) of ≥18 and ≤30 kg/m2
• No more than 2 bowel movements per day or fewer than 3 bowel movement per week
• Provision of signed and dated, written informed consent prior to any study specific procedures

You may not qualify if…

• Have participated in a [14C]-study within the last 6 months.
• Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).
• Male subjects who consume more than 21 units of alcohol per week or 3 units per day.

Where it is running

• Covance Global Clinical Research Unit Inc. — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.